BioCentury | Oct 24, 2020
Finance

Oct. 23 Quick Takes: RA Capital’s $461M new fund; plus venture rounds for Sirnaomics, 3D Medicines, Zhaoke, Orbus, Araris

New $461M venture fund for RA RA Capital raised $461 million for its Nexus Fund II, its second venture fund that like 2019’s $300 million Nexus I Fund will invest in private companies backed by the...
BioCentury | Jun 8, 2018
Financial News

Sirnaomics raises $25M series C1 round

Sirnaomics Inc. (Gaithersburg, Md.) raised $25 million in an untranched series C1 round led by Yuexiu New Industrial Investment. Fellow new investors Sangel Biomedical Venture Capital, HuaKong Equity Investment and Qianhai Shenghui Investment also participated....
BioCentury | Jun 7, 2018
Financial News

Sirnaomics raises $25M series C1 round

Sirnaomics Inc. (Gaithersburg, Md.) raised $25 million in an untranched series C1 round led by Yuexiu New Industrial Investment. Fellow new investors Sangel Biomedical Venture Capital, HuaKong Equity Investment and Qianhai Shenghui Investment also participated....
BioCentury | Aug 11, 2017
Tools & Techniques

K follows C in chemoproteomics

A year after publishing a map of druggable cysteines in the proteome, Ben Cravatt’s lab at Scripps has reported its chemoproteomics tools can also profile lysines. By identifying reactive lysines in dozens of proteins for...
BioCentury | Feb 16, 2017
Clinical News

Cotsiranib: Ph IIa started

Sirnaomics began a double-blind, placebo-controlled, U.S. Phase IIa trial to evaluate 20, 30 and 40 μg/cm 2 /day intradermal cotsiranib twice weekly for 4 weeks in about 24 patients. Patients will receive cotsiranib on 1...
BioCentury | Aug 11, 2016
Distillery Therapeutics

Therapeutics: S. aureus serine/threonine protein phosphatase (Stp1)

...aureus infection. Structural analysis of Stp1 complexed with a methylenedisalicylic acid-based tool compound that inhibited Stp1...
...and in vitro testing of commercially available methylenedisalicylic acid analogs, identified a compound that inhibited Stp1...
...could include optimizing and testing the compound in additional models of S. aureus infection. TARGET/MARKER/PATHWAY: S. aureus serine/threonine protein phosphatase (Stp1)...
BioCentury | May 5, 2016
Financial News

RNAi play Sirnaomics raises $10M

Sirnaomics Inc. (Gaithersburg, Md.) raised $10 million in a series B round from Hong Kong-based venture firm Value Measured Investment Ltd. CMO Michael Molyneaux told BioCentury the round will allow Sirnaomics to complete Phase I...
BioCentury | Apr 13, 2015
Clinical News

STP206 regulatory update

FDA granted Orphan Drug designation to STP-206 from Sigma-Tau to prevent necrotizing enterocolitis in premature infants with a birth weight of <=1.5 kg. STP-206 is in a Phase Ib/IIa trial for the indication. The product...
BioCentury | Feb 10, 2014
Clinical News

STP206: Phase I/II started

Sigma-Tau began a double-blind, placebo-controlled, dose-escalation, U.S. Phase I/II trial to evaluate 2 dose levels of once-daily STP206 in about 400 premature neonates with very low or extremely low birth weights. Sigma-Tau Group , Pomezia, Italy...
BioCentury | Jan 14, 2013
Clinical News

Sirnaomics preclinical data

In a rabbit skin papilloma model, topical STP909 stopped growth of papillomavirus. Details were not disclosed. Data were presented at the International Papillomavirus meeting in San Juan. The product consists of 2 siRNA duplexes against...
Items per page:
1 - 10 of 18